Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CK Life Sciences International (Holdings), Inc. ( (HK:0775) ) has provided an update.
CK Life Sciences International (Holdings) Inc. announced its plans to present new data from preclinical studies of investigational cancer vaccines at the 2025 AACR Annual Meeting. The vaccines target proteins such as PRAME, PD-L1, B7-H3, and Claudin 6, which are associated with different cancers. The company is also making progress in developing an AI-powered platform to improve vaccine design. While the preclinical results are promising, the company has not yet commenced clinical trials, and stakeholders are advised to exercise caution.
More about CK Life Sciences International (Holdings), Inc.
CK Life Sciences International (Holdings) Inc. operates in the biotechnology industry, focusing on the development of cancer vaccines. The company is engaged in research and development to create innovative treatments targeting specific proteins associated with various cancers, and it collaborates on projects involving artificial intelligence to enhance vaccine design.
YTD Price Performance: 85.37%
Average Trading Volume: 8,860,548
Technical Sentiment Signal: Sell
Current Market Cap: HK$7.3B
See more data about 0775 stock on TipRanks’ Stock Analysis page.